Treatment with Hydroxysafflor Yellow A reduces neuroinflammation and IL-17A in ischemic stroke, suggesting its anti-inflammatory and neuroprotective potential.
These findings suggest that an activated loop indeed exists between IL-17A and IL-17RA/ACT1/NF-κB after OGD/R, and HSYA treatment alleviated IL-17A release from astrocytes after OGD/R by inhibiting the IL-17RA/ACT1/NF-κB/IL-17A loop. These results further emphasize the anti-inflammatory and neuroprotective effects of HSYA and suggest that it may be a promising drug for treating IS.
No takes yet. Share an insight, caveat, or question.
SONG et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: